Posters and presentation information
Thank you for considering to present your work as a poster at this conference.
Digital poster preparation and submission
- Page size: Prepare your poster as you would normally do for printing. You can prepare your poster in sizes A1 or A0, as the page size is not important if only presenting digitally. However, print hardcopy posters in A1 portrait format. Larger posters and those in landscape format may not be displayed due to space constraints.
- Naming your poster files: Name your poster files as follows: <your surname>-Ven25-Poster.pdf. For example, for David Jones, name your file as Jones-Ven24-Poster.pdf. DO NOT name your poster files as, e.g., Oxford-poster, Venoms2025, Oxford-venoms-poster. Such files will be automatically rejected.
- Poster submission and deadlines: All poster presenters, whether attending virtually or in-person, are required to submit a digital version of their poster. Submit your final poster as PDF (<5MB) and via the link below no later than 20th August (we must have received your poster abstracts by 15th August). Late posters may not be included in the conference programme. Please DO NOT send your poster (or abstract) files by email. Please ensure you send us the very final version of your poster (as well as your poster abstract), as once published, it cannot be replaced.
Poster presentation
- Poster PDF files (required): Whether the presenter is attending virtually or in-person, poster PDF files are required, which will be made available via the secure ‘Download VEN25 Documents’ page to the conference participants. The participants will be able to ask questions via the Zoom chatbox during the conference. There is no specific time for presenting digital posters.
- Flash-talk videos (optional): We are pleased to offer poster presenters the opportunity to prepare a short video presentation about their poster and send it before the conference. The videos will be made available on the LPMHealthcare YouTube channel. Below is further information for sending your video presentation.
- Download the opening slide (VenOx25 flash talk first slide) and use it as the first slide of your presentation (see example: https://youtu.be/XatqenCd_IU?si=Yu1PooCD4JmSLAiz).
- Give your presentation (no longer than 5 minutes) using Zoom or another platform of your choice.
- Convert the video into a format compatible with YouTube (e.g., MP4).
- Send your video to VenomsOxford@gmail.com using a file transfer program, such as MailBigFile or WeTransfer.
- Hardcopy posters (optional): If attending in-person, you may bring along a printed copy of your poster (maximum A1 size) to be displayed during the conference. You may be assigned a specific day to display your poster.
- Any further information about the poster presentations will be available in the future.
Before uploading your poster, you must make sure that you follow ALL of the instructions above!
Accepted posters (unedited)
(Presenters in Bold)
If your abstract has been accepted for presentation but it does not appear in the list below, please let us know as soon as possible by email at VenomsOxford@gmail.com.
Action of marimastat, a synthetic broad-spectrum metalloprotease inhibitor, on the coagulotoxic effects of Lachesis muta (South-American Bushmaster) venom
Rafael S Floriano1, Vitória S Proença-Hirata1, Rogério Giuffrida1, Nelson J. Silva Jr2, Kristian A Torres-Bonilla3, Stephen Hyslop3, Enzo P Sousa4, Karen Morais-Zani4
1Laboratory of Toxinology and Cardiovascular Research, University of Western São Paulo, Presidente Prudente, 19023-130, Brazil
2Graduate Program in Environmental Sciences and Health, School of Medical and Life Sciences, Pontifical Catholic University of Goiás, Goiânia, 74605-010, Brazil
3Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, Campinas, 13083-888, Brazil 4Graduate Program in Toxinology, Laboratory of Pathophysiology, Butantan Institute, São Paulo, 05503-900, Brazil
In this work, we assessed the metalloprotease inhibitory action of marimastat (MMT) as an alternative pharmacological tool to anti-Bothrops/Lachesis antivenom (AV) on the coagulant effects of Lachesis muta venom (LMv). Enzymatic activity was assayed using azocasein as substrate. Factor X activation and thrombin-like activity were assessed using chromogenic substrates (S-2238 and S-2765); minimum coagulant dose (MCD) and fibrinogenolytic activity were assayed in human citrated plasma. MMT (0.03 mM) was determined as the minimum inhibitory concentration to abolish the caseinolytic activity of LMMv. The MCD of LMv was determined in 7.5 mg of venom/ml, with MMT (0.03 mM) being ineffective in preventing clotting formation, whereas AV (antivenom:venom ratio of 1:3 v/w) avoided the clotting formation in 240 sec of monitoring (p<0.05, n=3). Thrombin-like activity of LMv was significantly delayed only by AV (1:3) (p<0.05, n=3), and both of agents failed in preventing the factor X activation by this venom; LMv did not induce prothrombin (factor II) activation. LMv (7.5 mg/ml) exhibited a- and b-chain fibrinogenolysis. MMT (0.03 mM) reduced in 68±1.2% (p<0.05, n=3) the venom-induced a-chain fibrinogenolysis only at 5 min of incubation, with AV (1:3) being ineffective; in addition, MMT (0.03 mM) abolished the b-chain fibrinogenolysis at 5 min of incubation and significantly delayed this alteration at 30 and 90 min of incubation in 42±4.1% and 36±3.9%, respectively (p<0.05, n=3), whereas AV (1:3) produced superior b-fibrinogenolysis inhibition at 30 (69±1.1%) and 90 (65±2.1%) min of incubation. MMT (0.03 mM) did not show addictive protection when combined to AV (1:3) at any of these approaches. In conclusion, LMv exhibits haemostatic activity in vitro. MMT by itself or combined to AV does not appear to be a plausible pharmacological strategy to prevent haemostatic disorders caused by LMv, although the drug has prominently reduced the a- and b- fibrinogenolysis of LMv.
